Literature DB >> 2785367

Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.

V A Makinde1, G Senaldi, A S Jawad, H Berry, D Vergani.   

Abstract

Levels of C4d, a fragment of C4 generated during activation of the classical complement pathway, were measured in the plasma of 77 patients with rheumatoid arthritis and 30 healthy subjects. Disease activity was judged according to Ritchie's articular index to be mildly active in 31 (group 1), moderately active in 29 (group 2), and severely active in 17 patients (group 3). Plasma levels of C3d, a fragment of C3, and serum levels of C4, C3, and immune complexes were also measured. The ratios C4d/C4 and C3d/C3 were calculated. The C4d/C4 and C3d/C3 ratios and the levels of circulating immune complexes correlated with the degree of disease activity without significantly departing from linear trend and discriminated between patients with different grades of disease activity. C4d, C3d, C4, and C3 also correlated with disease activity but in a non-linear relationship. A significant correlation was found between C4d and C3d, and between C4d/C4 and C3d/C3. C4d and C4d/C4 also correlated with circulating immune complexes. These results indicate that indices of C4 and C3 activation, in particular the ratios C3d/C3 and C4d/C4, provide a sensitive assessment of disease activity in rheumatoid arthritis, and confirm the major part played by the classical complement pathway in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785367      PMCID: PMC1003745          DOI: 10.1136/ard.48.4.302

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease.

Authors:  R H Zubler; U Nydegger; L H Perrin; K Fehr; J McCormick; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

3.  Activation of the fourth component of complement (C4): assessment by rocket immunoelectrophoresis and correlation with the metabolism of C4.

Authors:  H Milgrom; J G Curd; R A Kaplan; H J Müller-Eberhard; J H Vaughan
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

4.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

5.  Behaviour of synovial complement C3 and C4 components in inflammatory and degenerative joint diseases, before and after synoviorthesis.

Authors:  R Gabay; A Micheli; G H Fallet
Journal:  Ann Rheum Dis       Date:  1975-04       Impact factor: 19.103

6.  Depressed synovial fluid levels of properdin and properdin factor B in patients with rheumatoid arthritis.

Authors:  S Ruddy; D T Fearon; K F Austen
Journal:  Arthritis Rheum       Date:  1975 Jul-Aug

7.  Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity.

Authors:  R K Mallya; D Vergani; D E Tee; L Bevis; F C de Beer; H Berry; E D Hamilton; B E Mace; M B Pepys
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

8.  Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group.

Authors: 
Journal:  Lancet       Date:  1978-11-11       Impact factor: 79.321

9.  Serum complement levels in rheumatoid arthritis. A longitudinal study of 43 cases with correlation of clinical and serological data including rheumatoid factor and thermolabile inhibitor of the F-II L.P. test.

Authors:  A F Schubart; R W Ewald; W C Schroeder; H J Rothschild; D N Bhatavadekar; P K Pullen
Journal:  Ann Rheum Dis       Date:  1965-09       Impact factor: 19.103

10.  Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.

Authors:  U E Nydegger; R H Zubler; R Gabay; G Joliat; C H Karagevrekis; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  18 in total

1.  Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 2.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

3.  Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.

Authors:  Roma Pahwa; Uma Kumar; Nibhriti Das
Journal:  Mol Cell Biochem       Date:  2016-02-23       Impact factor: 3.396

4.  Enlight: web-based integration of GWAS results with biological annotations.

Authors:  Yunfei Guo; David V Conti; Kai Wang
Journal:  Bioinformatics       Date:  2014-09-26       Impact factor: 6.937

5.  Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.

Authors:  A Familian; A E Voskuyl; G J van Mierlo; H A Heijst; J W R Twisk; B A C Dijkmans; C E Hack
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

6.  Levels of lectin pathway proteins in plasma and synovial fluid of rheumatoid arthritis and osteoarthritis.

Authors:  C G Ammitzboll; S Thiel; T Ellingsen; B Deleuran; Anette Jorgensen; J C Jensenius; K Stengaard-Pedersen
Journal:  Rheumatol Int       Date:  2011-04-03       Impact factor: 2.631

7.  Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals.

Authors:  Eva Biró; Rienk Nieuwland; Paul P Tak; Loes M Pronk; Marianne C L Schaap; Augueste Sturk; C Erik Hack
Journal:  Ann Rheum Dis       Date:  2007-01-29       Impact factor: 19.103

8.  Leucocyte complement receptor 1 (CR1/CD35) transcript and its correlation with the clinical disease activity in rheumatoid arthritis patients.

Authors:  D Anand; U Kumar; M Kanjilal; S Kaur; N Das
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

9.  Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.

Authors:  H Dauchel; P Joly; A Delpech; E Thomine; F Sauger; X Le Loet; P Lauret; F Tron; M Fontaine; J Ripoche
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  Morphological evidence that activated polymorphs circulate in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A McCarthy; J Bernhagen; M J Taylor; A S Hamblin; I James; P W Thompson; J D Perry
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.